Xeroderma pigmentosum

Malibu shines a light on CLINUVEL’s pioneering work in photomedicine

Retrieved on: 
Tuesday, March 5, 2024
Skin cancer, EPP, Pigment, Nervous system, Attacca Quartet, Growth, XP, Skin, Xeroderma pigmentosum, Global health, Life, Parker, Risk, Health, Vitiligo, Peptide, Melanocortin, Patient, Medicine, Knowledge, Research, Brain, Pharmaceutical industry

The Group’s CEO Dr. Philippe Wolgen also unveiled what is next for the most exciting biopharmaceutical firm in the field of photomedicine today.

Key Points: 
  • The Group’s CEO Dr. Philippe Wolgen also unveiled what is next for the most exciting biopharmaceutical firm in the field of photomedicine today.
  • Philanthropy is central to the work of Lady Gaga and Michael Polansky, Sean Parker and Alexandra Parker.
  • At the event in Malibu, CLINUVEL announced the Photomedicine Foundation, which will count Mr Polansky as a trustee.
  • CLINUVEL is grateful to have their support as we translate our pharmaceutical technology into PhotoCosmetics and give back to underserved communities.

ChromaDex Appoints Leading Aging and Neurodegenerative Disease Researcher, Dr. Vilhelm Bohr, to its Scientific Advisory Board (SAB)

Retrieved on: 
Thursday, January 12, 2023
Health, Genetics, General Health, Research, Science, Biotechnology, Neurodegeneration, XPA, ChromaDex, SAB, University of Copenhagen Center for Planetary Research, Teaching hospital, University, Ageing, Publication, NR, Molecular biology, Xeroderma pigmentosum, DNA, University Hospital (Newark, New Jersey), Degenerative disease, City, NAD, Stanford University, National Institutes of Health, Neurology, DNA repair, Infection, Oxidative stress, Laboratory, National Institute on Aging, Research, Cockayne syndrome, NIH, Cell, United States Air Force Scientific Advisory Board, Medical device, Diabetes, Ataxia–telangiectasia, Biochemistry

ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced it has appointed Dr. Vilhelm (Will) Bohr, M.D., Ph.D., D.Sc.

Key Points: 
  • ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced it has appointed Dr. Vilhelm (Will) Bohr, M.D., Ph.D., D.Sc.
  • Dr. Bohr is one of the world’s most published researchers on aging and neurodegenerative disease with over 590 journal publications.
  • His research has been conducted in models of Alzheimer’s disease, age-related hearing loss and other conditions resulting from age-related decline.
  • “Dr.

CLINUVEL Trial Results Show Drug Reduces DNA Damage

Retrieved on: 
Sunday, January 15, 2023
EPP, Swelling, Afamelanotide, Skin cancer, Sunburn, Xeroderma pigmentosum, DNA, Stress (linguistics), Xeroderma, Skin, Risk, DNA repair, Patient, Hormone, Physician, Life expectancy, Clinical trial, Melanocortin, Pigment, Inflammation, XP, Light, Disorder, Pharmaceutical industry, Dietary supplement, Black Beach

MELBOURNE, Australia, Jan. 16, 2023 (GLOBE NEWSWIRE) -- Results from a clinical trial in a genetic DNA repair disorder show that a new drug – afamelanotide – may be able to reduce the development of skin cancers.

Key Points: 
  • MELBOURNE, Australia, Jan. 16, 2023 (GLOBE NEWSWIRE) -- Results from a clinical trial in a genetic DNA repair disorder show that a new drug – afamelanotide – may be able to reduce the development of skin cancers.
  • The trial results are the first showing the potential of afamelanotide, a melanocortin drug under development by CLINUVEL, to protect and treat patients with xeroderma pigmentosum (XP), a rare disorder which causes extreme rates of skin cancers and forces patients to live in the dark.
  • “Our first clinical trial results demonstrate that afamelanotide in adult XP patients can reduce key markers of light and ultraviolet DNA damage, suggesting we may be able to reduce the risk and frequency of skin cancers in these patients.”
    Xeroderma pigmentosum affects patients’ ability to repair DNA skin damage following exposure to light, particularly ultraviolet (UV) radiation.
  • Note to media: CLINUVEL has released further investor and technical releases on results from the CUV156 study.

CLINUVEL expands DNA Repair Program

Retrieved on: 
Wednesday, March 24, 2021
Branches of biology, Biology, Senescence, DNA repair, Cellular processes, Molecular genetics, Mutation, Nucleotide excision repair, DNA damage, Melanocortin 1 receptor, Xeroderma pigmentosum, XPC

Afamelanotide, the active ingredient in SCENESSE, improves the function of skin cells which have incurred photodamage and assists these cells to repair DNA through several mechanisms, including nucleotide excision repair (NER).

Key Points: 
  • Afamelanotide, the active ingredient in SCENESSE, improves the function of skin cells which have incurred photodamage and assists these cells to repair DNA through several mechanisms, including nucleotide excision repair (NER).
  • XP-C results from a defect in one of the genes (chromosome 3p25.1) responsible for replicating proteins involved in a DNA repair process known as nucleotide excision repair (NER).
  • CLINUVEL has published an in-depth video on DNA damage and repair and the eight XP complementation groups.
  • CLINUVELs Scientific Communiqu Series provides an extensive overview of DNA damage and repair, with Communiqu VIII focused on DNA Repair Mechanisms and Communiqu IX looking at the role of the Melanocortin-1 Receptor (MC1R) in DNA Repair.

First patient dosed in SCENESSE® DNA Repair Program

Retrieved on: 
Tuesday, September 15, 2020
Branches of biology, Biology, Genodermatoses, RTT, Xeroderma pigmentosum, DNA repair, Afamelanotide, ERCC2, XPC

Following the treatment of a patient suffering from xeroderma pigmentosum (XP), a disease characterised by an inborn insufficiency to repair DNA damaged by sun exposure, Australian based CLINUVEL PHARMACEUTICALS is the first company worldwide to use a systemic therapy to repair DNA.

Key Points: 
  • Following the treatment of a patient suffering from xeroderma pigmentosum (XP), a disease characterised by an inborn insufficiency to repair DNA damaged by sun exposure, Australian based CLINUVEL PHARMACEUTICALS is the first company worldwide to use a systemic therapy to repair DNA.
  • CLINUVELs drug SCENESSE (afamelanotide 16mg) belongs to a group of hormones which have been shown to reduce UV-induced damage to DNA (photoproducts) and assist in DNA regeneration.1 The Company is running a staged clinical program to confirm the ability of SCENESSE to repair the DNA in skin cells, focusing initially on XP.
  • XP is a genetic disease which has served as a human model for studying the insufficiency of human DNA repair.
  • Following confirmation of safety of the drug product in this patient, CLINUVEL will conduct two further studies as part of the DNA Repair Program.

CLINUVEL progresses innovative DNA Repair Program

Retrieved on: 
Thursday, September 10, 2020
Branches of biology, Biology, Senescence, Biotechnology, DNA replication, RTT, Xeroderma pigmentosum, DNA repair, DNA, Genetics, DNA polymerase eta, ERCC4

Human biology contains complex mechanisms to protect itself from UV damage and restore cellular DNA to its original state.

Key Points: 
  • Human biology contains complex mechanisms to protect itself from UV damage and restore cellular DNA to its original state.
  • Our task is to confirm how DNA regeneration occurs within genetically affected patients and healthy subjects.
  • Following decades of clinical experience with SCENESSE, CLINUVEL is now accelerating a comprehensive DNA Repair Program by first treating patients with the rare genetic disorder xeroderma pigmentosum (XP) who have the most extreme deficiencies in their DNA repair processes, leading to a 10,000-fold increase in their risk of skin cancer.
  • The first clinical results from the DNA repair program are expected to be reported in 2021.